Brief summary of the agreement
Anyone is free:
· to copy, distribute, and display the work;
· to make derivative works;
· to make commercial use of the work;
Under the following conditions: Attribution
· the original author must be given credit;
· for any reuse or distribution, it must be made clear to others what the license terms of this work are;
· any of these conditions can be waived if the authors gives permission.
Statutory fair use and other rights are in no way affected by the above
Author Biographies
Alaa Aboutaam
Department of Dermatology and Venereology, Ibn Rochd University Hospital, Casablanca, Morocco
Fouzia Hali
Department of Dermatology and Venereology, Ibn Rochd University Hospital, Casablanca, Morocco
Kenza Baline
Department of Dermatology and Venereology, Ibn Rochd University Hospital, Casablanca, Morocco
Meryem Regragui
Department of Anatomy and Pathology, Ibn Rochd University Hospital, Casablanca, Morocco
Farida Marnissi
Department of Anatomy and Pathology, Ibn Rochd University Hospital, Casablanca, Morocco
Soumiya Chiheb
Department of Dermatology and Venereology, Ibn Rochd University Hospital, Casablanca, Morocco
Main Article Content
Morbihan disease: treatment difficulties and diagnosis: a case report
Alaa Aboutaam
Fouzia Hali
Kenza Baline
Meryem Regragui
Farida Marnissi
Soumiya Chiheb
Abstract
Morbihan disease (MD) is a rare entity. Its nosography is unclear and its therapeutic management is difficult. We report a new case of MD. We report a case of a 51-year-old patient consulted in our department for a one year facial edema, erythema and papules reported by him, for which the patient was treated with cyclins, local and general corticotherapy, without improvement. The clinical examination found an important edema of the front and eyelids with an erythema of the cheeks covered with a few telangiectasias. The clinical, biological and histological findings lead to a diagnosis of Morbihan disease after excluding other diseases. Due to previous therapeutic failures, the patient was put on isotretinoin and furosemide with slight improvement. The particularity of our observation lies in the rarity and especially in the therapeutic difficulties encountered during this disease.
AJOL is a Non Profit Organisation that cannot function without donations.
AJOL and the millions of African and international researchers who rely on our free services are deeply grateful for your contribution.
AJOL is annually audited and was also independently assessed in 2019 by E&Y.
Your donation is guaranteed to directly contribute to Africans sharing their research output with a global readership.
Once off donations here:
For annual AJOL Supporter contributions, please view our Supporters page.
Tell us what you think and showcase the impact of your research!
Please take 5 minutes to contribute to our survey so that we can better understand the contribution that African research makes to global and African development challenges. Share your feedback to help us make sure that AJOL's services support and amplify the voices of researchers like you.